Transcode Therapeutics, Inc. (RNAZ) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Transcode Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, utilizing a proprietary iron-oxide nanoparticle delivery platform (TTX). The company's lead candidate, TTX-MC138, targets miRNA-10b to inhibit metastatic tumor cell survival. The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2.32) million | $(10.84) million | $(14.46) million |
| Operating Expenses | $(2.17) million | $(10.57) million | $(15.32) million |
| Cash and Cash Equivalents (Sept 30, 2024) | $1.88 million | ||
| Accumulated Deficit | $(57.26) million | ||
| Net Cash Used in Operating Activities (YTD) | $(10.19) million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $3.15 million in Q3 2024 compared to Q3 2023, and $4.75 million on a YTD basis. This reduction is attributed to cost-cutting measures, including headcount reductions (from 19 employees in late 2022 to 8 employees as of Sept 30, 2024) and reduced spending on materials and consulting.
- Grant Income: Grant income decreased significantly YTD 2024 ($39k) compared to YTD 2023 ($896k) as the initial NIH SBIR award concluded in March 2024. A new NIH award was received in September 2024.
- Currency Loss: The company recognized a currency exchange loss of $157k in Q3 2024 and $285k YTD 2024 due to Euro-denominated vendor billings, a non-existent expense in the prior year.
- Capital Raising: The company raised approximately $9.32 million in net proceeds from equity sales during the first nine months of 2024, including a July 2024 public offering.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash ($1.88 million) is projected to fund operations only into late 2024. Additional capital is required to continue clinical trials and operations.
- Nasdaq Delisting Risk: The company received notices of non-compliance with Nasdaq listing rules regarding bid price, equity, and shareholder approval. While an extension was granted in November 2024 to regain compliance, failure to do so could result in delisting to the OTC market, severely impacting liquidity and capital raising ability.
- Clinical Progress: The Phase 0 microdose trial showed promising delivery of TTX-MC138 to metastatic lesions. The Phase 1/II clinical trial commenced in Q3 2024, with the second cohort dosing approved in October 2024.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective due to unremediated material weaknesses in internal control over financial reporting.
- Collaborations: A strategic collaboration with MD Anderson was terminated, though the clinical trial at that site continues. A collaboration with Debiopharm was paused due to insufficient results.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the "late 2024" cash runway estimate and the substantial doubt disclosure.
- Nasdaq Compliance: Monitor the company's progress in meeting the specific deadlines (Nov 22 and Dec 31, 2024) to avoid delisting.
- Phase 1 Trial Data: Await safety and tolerability data from the Phase 1 trial, particularly regarding the second cohort dosing.
- Internal Controls: Review future filings for updates on the remediation of material weaknesses in financial reporting.
- Dilution Risk: Assess the potential dilution from the large number of outstanding warrants (over 12 million shares) and future equity offerings required to fund operations.